On September 3, GENSCRIPT BIO rose 3.29% in regular trading, trading at 36.74 HKD/share, with turnover of approximately 120 million HKD. The stock continued its upward momentum following a series of positive catalysts including a strong interim earnings beat and a significant upward revision to full-year guidance.

The company recently reported H1 results with revenue of approximately USD 404 million, up 27.3% year-over-year, and adjusted net profit of USD 62.5 million, surging 203.3% year-over-year, substantially exceeding market expectations. The life sciences segment delivered revenue of USD 319 million, up 28.8%, with adjusted operating profit doubling to USD 94 million. Notably, AIDD-related business achieved over 100% year-over-year growth, marking three consecutive half-year periods of rapid expansion.

The company raised its full-year guidance, targeting life sciences revenue growth of 25%-30%, with AIDD-related order revenue expected to maintain a doubling growth trajectory. Multiple institutions including CICC, Huatai Securities, and BOCOM International have raised target prices, with CICC lifting its target by 78.8% to 32 HKD, citing AIDD as a long-term structural growth driver for the company's gene-to-protein integrated platform.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)